title: A comparison of netilmicin and tobramycin therapy in patients with renal impairment.
abstract: We evaluated the toxicity and efficacy of netilmicin and tobramycin in 89 older adults with serious bacterial infections and pre-existing renal impairment in a prospective, blinded, randomized trial. Complete resolution or improvement of infection occurred at 34/36 (94%) evaluable sites in netilmicin-treated patients and at 26/31 (84%) evaluable sites in tobramycin-treated patients. 10/44 (23%) netilmicin- and 7/45 (16%) tobramycin-treated patients experienced nephrotoxicity during treatment. The mean serum creatinine level improved significantly at the end of therapy compared to pre-treatment in those patients who did not experience nephrotoxicity in both treatment groups. 5/19 (26%) netilmicin-treated patients and 2/18 (11%) tobramycin-treated patients assessable for ototoxicity experienced decrements in auditory thresholds. Ototoxic netilmicin-treated patients had higher serum netilmicin levels than did non-ototoxic patients. Patients who experienced ototoxicity were not more likely to have experienced nephrotoxicity. The rates of toxicity were not statistically different and were similar to those seen in studies of patients with normal pre-treatment renal function.
authors.affiliation: Department of Internal Medicine, School of Medicine, St. Louis University Medical Center, MO 63104.
authors.forename: G J
authors.initials: GJ
authors.lastname: Gorse
authors.forename: J M
authors.initials: JM
authors.lastname: Bernstein
authors.forename: R E
authors.initials: RE
authors.lastname: Cronin
authors.forename: P S
authors.initials: PS
authors.lastname: Etzell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000150:complications* / Q000188:drug therapy*; D006312:Hearing Loss, Bilateral / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D014031:Tobramycin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D009428:Netilmicin; D014031:Tobramycin